28 June 2024 - NICE has recommended CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) for immediate reimbursement by NHS England.

The agency’s positive opinion, which specifically applies to adults with severe or moderately severe haemophilia B without a history of factor IX inhibitors, reverses its previous decision to reject the therapy.

Read PM Live article